Parkside Financial Bank & Trust Has $1.47 Million Position in Pfizer Inc. (NYSE:PFE)

Parkside Financial Bank & Trust lifted its holdings in Pfizer Inc. (NYSE:PFE) by 21.6% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 51,050 shares of the biopharmaceutical company’s stock after acquiring an additional 9,073 shares during the quarter. Parkside Financial Bank & Trust’s holdings in Pfizer were worth $1,470,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Briaud Financial Planning Inc purchased a new position in shares of Pfizer during the 3rd quarter valued at $30,000. GoalVest Advisory LLC grew its stake in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. acquired a new position in Pfizer in the third quarter worth approximately $34,000. VisionPoint Advisory Group LLC raised its position in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new stake in Pfizer in the fourth quarter valued at approximately $36,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Guggenheim assumed coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Eleven research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $36.33.

Pfizer Price Performance

NYSE PFE traded down $0.13 during trading hours on Wednesday, reaching $26.19. 5,086,980 shares of the company’s stock were exchanged, compared to its average volume of 41,627,031. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The firm has a fifty day moving average of $27.07 and a 200-day moving average of $28.52. Pfizer Inc. has a one year low of $25.23 and a one year high of $40.37. The stock has a market cap of $148.30 billion, a PE ratio of 73.11, a price-to-earnings-growth ratio of 1.18 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same period last year, the business earned $1.14 earnings per share. The business’s quarterly revenue was down 41.3% on a year-over-year basis. On average, equities research analysts predict that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.